HA-100

HA-100 is an inhibitor of PKA and PKC used in studies of MAPK / ERK Signaling and GPCR Signaling. It is especially relevant in cancer and cell signaling models, where defined compound exposure can be linked to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and receptor-driven second-messenger signaling and desensitization dynamics.

By inhibiting PKA and PKC, HA-100 can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and receptor-driven second-messenger signaling and desensitization dynamics. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving PKA and PKC
• Pathway perturbation studies connected to MAPK / ERK Signaling and GPCR Signaling
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, HA-100 is appropriate when a defined chemical perturbant is needed to connect PKA and PKC with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.